-+ 0.00%
-+ 0.00%
-+ 0.00%

Enlivex Completes Patient Enrollment In Phase II Stage Of Randomized, Controlled, Blinded Phase I/II Trial Of Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Benzinga·04/21/2025 12:35:47
Listen to the news

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage.